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Abstract
Objective: Cystic fibrosis (CF) is a chronic multisystemic hereditary disease for which a multidisciplinary approach 
must be taken. The objective of this study was to show the evolution of a group of patients with CF after the 
implementation of multidisciplinary treatment. Methods: A retrospective study involving 19 patients (6-29 years 
of age) under clinical follow-up treatment at the University of São Paulo at Ribeirão Preto School of Medicine 
Hospital das Clínicas, located in the city of Ribeirão Preto, Brazil. The patients were divided into two groups: 
6-12 (6-12 years of age) and 13+ (> 12 years of age). We collected data regarding body mass index (BMI), Z score, 
Shwachman score (SS), number of exacerbations/year, chronic colonization by Pseudomonas aeruginosa, and 
spirometric measurements (FVC, FEV1, FEV1%, and FEF25-75%). Data were collected at two different time points 
(before and after the implementation of the multidisciplinary treatment) and were analyzed with the Wilcoxon 
signed rank test. Results: The median age at the onset of symptoms was 10 months. In the 6-12 group, only 
BMI and FVC increased significantly. Although the other spirometric values increased, the differences were not 
significant. In the 13+ group, there were no significant differences between the two time points. There was a 
borderline significant decrease in SS and less than significant decreases in the spirometric measurements. However, 
the number of patients with alterations in volumes and flows decreased in both groups. Conclusions: Although our 
patient sample was small, the lack of changes in the spirometric parameters might reflect clinical and functional 
stability. In all of the patients evaluated, clinical, functional, and nutritional parameters remained stable throughout 
the study period. The implementation of a multidisciplinary approach might have contributed to this result.
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Resumo
Objetivo: A fibrose cística (FC) é uma doença hereditária, multissistêmica e crônica, para a qual é importante 
uma abordagem multidisciplinar. O objetivo deste estudo foi mostrar a evolução de um grupo de pacientes com 
FC após a implantação desse tipo de atendimento. Métodos: Foram analisados retrospectivamente 19 pacientes 
(idades entre 6 e 29 anos) em acompanhamento clínico no Hospital das Clínicas da Faculdade de Medicina de 
Ribeirão Preto da Universidade de São Paulo, na cidade de Ribeirão Preto (SP). Os pacientes foram divididos 
em dois grupos: grupo 6-12 (6-12 anos) e grupo 13+ (> 12 anos). Dados referentes a índice de massa corporal 
(IMC), escore Z, escore de Shwachman (ES), número de exacerbações/ano, colonização crônica por Pseudomonas 
aeruginosa e medidas espirométricas (CVF, VEF1, VEF1% e FEF25-75%) foram obtidos. Os dados foram coletados em 
dois momentos (antes e após a implantação de atendimento multidisciplinar) e foram analisados com o teste dos 
postos sinalizados de Wilcoxon. Resultados: A mediana de idade de início de sintomas foi de 10 meses. No grupo 
6-12, houve somente um aumento significativo do IMC e da CVF. As outras medidas espirométricas aumentaram, 
mas não significativamente. No grupo 13+, não houve diferenças significativas entre os dois momentos, sendo 
que o ES apresentou uma diminuição com significância limítrofe. Houve diminuição não significativa das medidas 
espirométricas. Entretanto, o número de pacientes com volumes e fluxos alterados diminuiu nos dois grupos. 
Conclusões: Apesar do grupo pequeno, a manutenção dos parâmetros espirométricos pode significar estabilidade 
clínica e funcional. Os pacientes estudados mantiveram estabilidade clínica, funcional e nutricional durante o 
período, e a implantação de abordagem multidisciplinar pode ter contribuído nesse sentido.
Descritores: Fibrose cística; Espirometria; Índice de massa corporal; Modalidades de fisioterapia.
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analysis—in which we included patients who had 
been diagnosed with CF based on two positive 
pilocarpine iontophoresis sweat test results and 
whose clinical profiles were consistent with 
the diagnosis.(11) We included only patients 
who were under regular clinical follow-up 
treatment at the University of São Paulo at 
Ribeirão Preto School of Medicine Hospital das 
Clínicas, located in the city of Ribeirão Preto, 
Brazil, and were able to perform the spirometry 
maneuvers. The variables were analyzed at two 
different time points: before and four years 
after the opening of the Multidisciplinary Cystic 
Fibrosis Outpatient Clinic at the institution (in 
2003 and 2007, respectively). At this outpatient 
clinic, patients were simultaneously evaluated 
by pulmonologists, gastroenterologists, nurses, 
physical therapists, nutritionists, psychologists, 
and social workers. All of the patients included 
in the present study were submitted to 
systematic collection of respiratory secretion for 
microbiological study, every one or two months. 
The collection was performed by a nurse or a 
physical therapist on the multidisciplinary team. 
Samples were collected by oropharynx swab, 
spontaneous expectoration, sputum induction, 
or oropharyngeal aspiration. 
All patients were instructed to perform 
the same respiratory therapy techniques for 
airway clearance, including postural drainage, 
percussion, flow maneuvers, mechanical vibration, 
and manual vibration with compression for 
young children. Older children and adults were 
taught respiratory exercises (with the use of the 
shaker or flutter technique), assisted cough or 
cough stimulation techniques (such as huffing), 
diaphragmatic and pursed-lip breathing (in 
order to facilitate the deflation of the peripheral 
airways), and analysis of posture (with an 
emphasis on stretching). The importance of 
adhering to physical therapy and of the correct 
performance of the exercises (performed by 
the patients themselves or their mothers) were 
emphasized at every evaluation. 
Patient nutritional status was evaluated 
once every one or two months and consisted of 
measuring weight and height, in order to calculate 
the body mass index (BMI), as well as analyzing 
the dietary report. The importance of adhering 
to the diet prescribed was emphasized. 
For the analysis of most of the data collected, 
the 19 patients included in the present study 
Introduction
Cystic fibrosis (CF) is a fatal disease and is the 
most common autosomal recessive hereditary 
disease in White individuals. Over 1,500 
CF-related mutations have been identified.(1,2) 
The first such mutation was identified on the 
long arm of chromosome 7 and encodes cystic 
fibrosis transmembrane conductance regulator, 
a 1,480-amino acid protein that functions as 
a chloride channel in the apical membrane of 
epithelial cells. When there is a defect in this 
protein, the viscosity of secretions changes, 
which leads principally to malabsorption, sweat 
electrolyte loss, and changes in pulmonary 
secretions, leading to decreased mucociliary 
clearance.(3) 
The phenotypic presentations (respiratory 
and gastrointestinal) differ from patient to 
patient. However, progressive pulmonary 
impairment is the most common cause of death. 
Increased secretion viscosity and the consequent 
difficulty in drainage lead to inflammation and 
infection that become chronic, with gradual 
loss of pulmonary function and progression 
to respiratory failure.(4-6) Therefore, control 
of pulmonary infections, improvement in the 
clearance of bronchial secretions, enzyme 
replacement therapy, and nutrition therapy 
contribute to reducing CF-related morbidity and 
mortality.(7-9) 
Specialized, multidisciplinary treatment of 
patients with CF has been shown to have a 
strong relationship with decreased severity of 
profiles and increased survival. The World Health 
Organization (WHO) and the International 
Cystic Fibrosis (Mucoviscidosis) Association 
recommend the implementation of specialized 
centers, even in developing countries, since the 
treatment given at such centers can improve 
clinical outcomes and survival, principally when 
the treatment targets nutrition and lung disease 
control.(8-10) 
The objective of the present study was to 
describe the clinical and pulmonary functional 
evolution of a group of patients with CF after 
the implementation of a multidisciplinary 
outpatient clinic. 
Methods
We conducted a descriptive study—with 
retrospective data collection and cross-sectional 
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values proposed by Knudson et al., and compared 
with data from other studies conducted in 
Brazil.(15,16) The spirometric tests performed and 
the characteristics of the spirometer used were 
in accordance with the standards established by 
the American Thoracic Society.(17) 
Chronic pulmonary colonization by P. 
aeruginosa was defined as the presenting with 
evidence of the bacterium in the bronchial tree 
for at least six months (three successive positive 
cultures for P. aeruginosa, with an interval of 
at least one month between each) and having 
no detectable, direct signs of infection or tissue 
damage, such as inflammation and fever.(18) 
Acute pulmonary exacerbation was defined 
as the occurrence of one or more of the 
following signs and symptoms: increased cough; 
increased expectoration; fever; anorexia; weight 
loss; school absenteeism; work absenteeism; 
decreased exercise tolerance; decreased oxygen 
saturation; new pulmonary auscultation 
findings; new radiological findings; or an abrupt 
reduction (> 10%) in FEV1.
(19) 
The statistical analysis of the data collected 
at the two time points was performed with the 
statistical program GraphPad Prism (GraphPad 
Software, San Diego, CA, USA), and the Wilcoxon 
signed rank test for paired samples was used, 
with an alpha error of 5%, since most of the 
data presented non-normal distribution and the 
number of individuals in each group was quite 
small. For all of the other data described, statistical 
analysis of the medians was performed. 
The present study was approved by the 
Research Ethics Committee of the University of 
São Paulo at Ribeirão Preto School of Medicine 
(protocol no. 2094/2009). 
Results
We studied the data of 19 patients who were 
able to perform spirometry, with the exception 
of the final data of 2 male patients who died 
during the follow-up period: 1 due to respiratory 
failure and 1 due to dilated cardiomyopathy. Of 
the 19 patients, 7 were female (5 in the 6-12 
group and 2 in the 13+ group), and 12 were 
male. The 19 patients accounted for 30% of all 
patients who were under follow-up treatment at 
our facility in 2003. In addition, 1 patient moved 
to a different address. Of the 19 CF patients, 12 
(63%) had been diagnosed before the age of 2 
years, 6 (31%) had been diagnosed with CF by 
were divided into two groups, according to 
the initial age bracket: the 6-12 group (n = 8), 
which included children aged 6-12 years; and 
the 13+ group (n = 11), which included patients 
aged > 12 years. The results obtained for the 
two groups were analyzed at two different time 
points: in 2003 (before the implementation of 
the outpatient clinic) and in 2007 (four years 
after the implementation of the outpatient 
clinic). 
All of the patients were wearing light clothes 
and no shoes when they were weighed. Patient 
height (in cm) was measured with a stadiometer 
(Harpenden; British Indicators, Burgess Hill, 
United Kingdom), with the patients standing 
straight and looking ahead, heels pressed 
against the wall. The data obtained were used 
to calculate the BMI. For the two groups, the 
analysis of the BMI was based on the median, 
as well as on the calculation of the Z score. 
The evaluation of the BMI was used for the 
clinical definition of the nutritional status and 
followed the recommendations put forward in 
international consensuses. The data obtained 
were compared with those of the specific BMI 
distribution curve proposed by the WHO for 
patients aged 2-19 years. Patients who were 
below the 10th percentile were considered to be 
undernourished, and those who were between 
the 10th and 25th percentiles were considered 
to be at nutritional risk. For patients over 19 
years of age, we also used the specific WHO 
classification: BMI < 20 kg/cm2 = underweight; 
BMI 20-25 kg/cm2 = normal weight; and BMI > 
25 kg/cm2 = overweight.(12-14) 
The Shwachman score (SS), the number of 
exacerbations per year, and the presence of 
chronic colonization by Pseudomonas aeruginosa 
were also analyzed. 
Pulmonary function measurements, all of 
which were expressed as the percentage of 
predicted, were as follows: FVC; FEV1; FEV1/FVC 
ratio; and FEF25-75%. Spirometry was performed 
with a Vitatrace VT 130 spirometer (Pró Médico 
Ltda., Rio de Janeiro, Brazil), and the curves 
were registered on paper. We traced a volume-
time curve, on which the measurements of FVC, 
FEV1, FEV1/FVC ratio, and FEF25-75%, corrected for 
body temperature and blood pressure standards, 
were based. The values of the best of five forced 
exhalations were registered as percentages of 
predicted, in accordance with the reference 
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only, being borderline significant for FEV1. In the 
6-12 group, the number of patients with changes 
in volumes and flows decreased. However, the 
number of patients with changes in the FEV1/
FVC ratio remained the same. In the 13+ group, 
all medians decreased. However, the difference 
was not statistically significant. The number of 
patients with changes in FVC and FEV1 remained 
the same. However, the number of patients with 
changes in FEF25-75% and in the FEV1/FVC ratio 
decreased when the following cut-off points 
were considered: 80% of the predicted values 
for FVC and FEV1; 70% of the predicted value 
for FEF25-75%; and 75% of the predicted value for 
the FEV1/FVC ratio. These data can be seen in 
Tables 2 and 3. 
Discussion
There are various norms stating that 
specialized CF treatment centers should have 
multidisciplinary teams in order to facilitate 
the overall evaluation of patients. However, this 
results in an increase in the complexity and 
costs of such centers, principally in developing 
countries. Nevertheless, in recent years, the 
implementation of a multidisciplinary approach 
at such centers has effectively slowed the decline 
in pulmonary function and the worsening of CT 
findings.(8-10,20) 
Although all of the patients under study 
presented with early symptom onset and were 
diagnosed in a timely manner, they were divided 
into two groups by current age bracket and 
the age of 6 years, and 1 had been diagnosed 
with CF at the age of 12 years. The median age 
at diagnosis was 10.5 months. 
We observed a significant increase in the 
BMI in the 6-12 group during the study period. 
However, all of the patients presented with a 
similar nutritional risk at the two evaluation 
time points, as did all of the patients aged 
13-19 years in 2003. In 2007, 3 of the 4 patients 
over 19 years of age presented with normal 
BMI, and 1 migrated to the overweight group. 
However, this patient was a weightlifter, and the 
weight gain observed was due to an increase 
in muscle mass. The BMI Z score for the group 
formed by patients younger than 19 years of 
age was analyzed, and there was no significant 
difference between the medians (−0.4 in 2003 
vs. −0.39 in 2007; p = 0.51). Although the SS 
was lower at the second evaluation time point 
than it was at the first evaluation time point, in 
both groups, the difference was not statistically 
significant. In the 13+ group, however, there 
was a borderline significant decrease in the SS. 
There were no significant differences between 
the two time points in terms of the number of 
exacerbations, and the patients who presented 
with colonization by P. aeruginosa in 2003 also 
did so in 2007: 1 patient in the 6-12 group and 
6 in the 13+ group. These data are summarized 
in Table 1. 
The median FVC, FEV1, and FEF25-75% (in 
percentage of predicted) increased in the 
6-12 group during the study period. However, 
this increase was statistically significant for FVC 
Table 1 - Body mass index, Shwachman score, and number of exacerbations per year in the two groups under 
study at the two evaluation time points.a




p* 13+ group, 2003 13+ group, 
2007
p*
BMI, kg/m2 15.3 (13.6-18.5) 17.2 (14.8-20.5) 0.04 20.0 (13.5-21.5) 18.8 (16.9-28.8) 0.84
Exacerbations/year, n 3.12 (2.00-5.00) 2.12 (0.00-4.00) 0.48 2.5 (0.0-5.0) 2.5 (0.0-4.0) 0.62
Shwachman score 77.5 (55.0-90.0) 75.0 (65.0-85.0) 0.46 90.0 (55.0-90.0) 70 (50.0-85.0) 0.09
BMI: body mass index. aValues expressed as median (range). *Wilcoxon signed rank test for paired samples.
Table 2 - Pulmonary function values for FVC, FEV1, FEV1/FVC ratio, and FEF25-75% in the two groups under 
study at the two evaluation time points.a




p* 13+ group, 2003 13+ group, 2007 p*
FVC, % of predicted 78.0 (45.0-101.0) 86.0 (70-91) 0.01 82.5 (29.0-104.0) 63.0 (42.0-104.0) 0.54
FEV1, % of predicted 70.0 (61.0-104.0) 80.0 (66.0-81.0) 0.07 70.5 (30.0-96.0) 45.0 (20.0-104.0) 0.46
FEV1/FVC, % of predicted 82.5 (73.0-91.0) 83.0 (68.0-88.0) 0.62 72.0 (41.0-84.0) 64.0 (38.0-84.0) 0.46
FEF25-75%, % of predicted 55.0 (38.0-115.0) 64.0 (29.0-96.0) 0.68 38.5 (5.0-100.0) 19.5 (6.0-80.0) 0.54
aValues expressed as median (range). *Wilcoxon signed rank test for paired samples.
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values coincided with an improvement in BMI, 
as would be expected, because there is a strong 
correlation between BMI and FVC, which 
reflects lung size and appropriate developmental 
conditions. These incidental findings of improved 
pulmonary function in children are similar to 
those of other studies involving similarly aged 
patients and are due to the fact that pulmonary 
function and lung growth can improve by the 
age of 12 years.(24) In the 13+ group, the medians 
decreased, although not significantly. This was 
also observed in similarly aged CF patients in a 
study conducted in southern Brazil,(25) as well as 
in international studies.(26) In the present study, 
the median volumes and flows were similar 
to the median FVC and FEV1 reported in the 
aforementioned study conducted in southern 
Brazil.(25) However, the FEF25-75% values observed 
in the present study were slightly higher than 
were those reported in the aforementioned 
study (median of 46.0% vs. 35.0% at the age of 
10 years and of 12.5% at the age of 18 years). 
The values found in the present study were also 
higher than were those found in another study 
conducted in Brazil,(27) which investigated adult 
patients with later-onset CF and, therefore, 
milder disease (FVC = 77% vs. 59%; and FEV1 
= 63% vs. 44%). 
In the present study, FEV1 values were 
below the mean for height, even in the younger 
patients, and we underscore the importance of 
FEV1 as an analytical factor for prognosis and 
follow-up, as described by other authors.(8,9,26) 
In the present study, airway obstruction was 
more severe in the small airways, as evidenced 
by the FEF25-75% values obtained. Although this 
measurement is not routinely used, FEF25-75% has 
been shown to be important for the analysis of 
pulmonary function in patients with CF, since 
early and intense small airway impairment can 
occur in young children, as a result of early-
were analyzed at two different time points. 
Despite the small sample size, we chose to 
divide the patients as described above because 
the evolution of CF varies by age bracket. In 
addition, it is known that the health status 
of patients is less affected early in life, when 
lung damage is not extensive. However, for the 
analysis of the BMI Z score in relation to the 
standard, we chose to analyze the sample as a 
whole, since the reference curve for BMI does 
not vary between birth and 19 years of age. The 
data for the comparison between the two time 
points, as well as those for patients over 18 years 
of age, were analyzed on the basis of the median. 
Although there was a significant increase in the 
BMI in the 6-12 group, the patients remained 
in the same percentile during the follow-up 
period. In the 13+ group, the BMI decreased, 
although not significantly. In the two groups, Z 
scores also decreased, although not significantly. 
Although skinfold measurements are highly 
recommended by international consensuses, 
they were not used in the present study, because 
these data were not available for all patients in 
2003. The nutritional status of the patients in 
our study sample remained stable throughout 
the follow-up period. Preservation of nutritional 
status is one of the principal objectives of CF 
treatment, since malnutrition has a negative 
effect on ventilatory capacity, exercise tolerance, 
lung size, and pulmonary function, as well as 
predisposing to infection.(21-23) 
In the 6-12 group, the number of patients 
with changes in lung volumes decreased. In 
addition, there was a significant increase in 
FVC and a borderline significant increase in 
FEV1. The medians of other flows also increased, 
although not significantly. This suggests that 
the pulmonary function of younger patients 
was preserved throughout the four-year study 
period. The maintenance of pulmonary function 
Table 3 - Distribution of the patients with altered pulmonary function in the two groups under study at the 
two evaluation time points.a




13+ group,  
2003
13+ group,  
2007
(n = 8/19) (n = 8/17) (n = 11/19) (n = 9/17)
FVC < 80% of predicted 4 (50.0) 1 (12.5) 4 (36.4) 4 (44.4)
FEV1 < 80% of predicted 5 (62.5) 3 (37.5) 6 (54.5) 6 (66.6)
FEV1/FVC < 75% of predicted 1 (12.5) 1 (12.5) 7 (87.5) 6 (66.6)
FEF25-75% < 70% of predicted 6 (75.0) 5 (62.5) 10 (90.9) 8 (88.8)
aValues expressed as n (%).
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significant beneficial effects in the study 
sample. However, the multidisciplinary treatment 
might have contributed to a slight functional 
improvement in the younger patients. In the 
older patients, the multidisciplinary treatment 
might have contributed to the maintenance of 
clinical stability, nutritional status, and number 
of patients colonized by P. aeruginosa, as well 
as to the stability of the SS. In addition, the 
decrease in the number of individuals with 
changes in lung volumes and flows, as well as 
the improvement in FVC, observed in the children 
aged 6-12 years suggests that not every change 
detected was definitive, which is an additional 
stimulus for taking a multidisciplinary approach 
to such patients. 
In order to determine which measures can 
effectively improve the quality of life of such 
patients, as well as the long-term effects of such 
measures, multicenter studies involving larger 
patient samples are needed, since therapeutic 
objectives that are more effective can only 
be established after an understanding of the 
evolution of CF has been gained. 
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